Your browser doesn't support javascript.
loading
Molecular Profiling of Circulating Tumour Cells Identifies Notch1 as a Principal Regulator in Advanced Non-Small Cell Lung Cancer.
Mariscal, Javier; Alonso-Nocelo, Marta; Muinelo-Romay, Laura; Barbazan, Jorge; Vieito, Maria; Abalo, Alicia; Gomez-Tato, Antonio; Maria de Los Angeles, Casares de Cal; Garcia-Caballero, Tomas; Rodriguez, Carmela; Brozos, Elena; Baron, Francisco; Lopez-Lopez, Rafael; Abal, Miguel.
Afiliación
  • Mariscal J; Translational Medical Oncology, Health Research Institute of Santiago (IDIS), University Hospital of Santiago (SERGAS), Trav. Choupana s/n 15706 Santiago de Compostela, Spain.
  • Alonso-Nocelo M; Translational Medical Oncology, Health Research Institute of Santiago (IDIS), University Hospital of Santiago (SERGAS), Trav. Choupana s/n 15706 Santiago de Compostela, Spain.
  • Muinelo-Romay L; Translational Medical Oncology, Health Research Institute of Santiago (IDIS), University Hospital of Santiago (SERGAS), Trav. Choupana s/n 15706 Santiago de Compostela, Spain.
  • Barbazan J; Liquid Biopsy Analysis Unit, Health Research Institute of Santiago (IDIS), University Hospital of Santiago (SERGAS), Trav. Choupana s/n 15706 Santiago de Compostela, Spain.
  • Vieito M; Translational Medical Oncology, Health Research Institute of Santiago (IDIS), University Hospital of Santiago (SERGAS), Trav. Choupana s/n 15706 Santiago de Compostela, Spain.
  • Abalo A; Translational Medical Oncology, Health Research Institute of Santiago (IDIS), University Hospital of Santiago (SERGAS), Trav. Choupana s/n 15706 Santiago de Compostela, Spain.
  • Gomez-Tato A; Translational Medical Oncology, Health Research Institute of Santiago (IDIS), University Hospital of Santiago (SERGAS), Trav. Choupana s/n 15706 Santiago de Compostela, Spain.
  • Maria de Los Angeles CC; Liquid Biopsy Analysis Unit, Health Research Institute of Santiago (IDIS), University Hospital of Santiago (SERGAS), Trav. Choupana s/n 15706 Santiago de Compostela, Spain.
  • Garcia-Caballero T; School of Mathematics, University of Santiago de Compostela (Campus Vida), C/Lope Gomez de Marzoa s/n 15782 Santiago de Compostela, Spain.
  • Rodriguez C; School of Mathematics, University of Santiago de Compostela (Campus Vida), C/Lope Gomez de Marzoa s/n 15782 Santiago de Compostela, Spain.
  • Brozos E; Department of Morphological Sciences, School of Medicine, University of Santiago de Compostela, Spain.
  • Baron F; Translational Medical Oncology, Health Research Institute of Santiago (IDIS), University Hospital of Santiago (SERGAS), Trav. Choupana s/n 15706 Santiago de Compostela, Spain.
  • Lopez-Lopez R; Translational Medical Oncology, Health Research Institute of Santiago (IDIS), University Hospital of Santiago (SERGAS), Trav. Choupana s/n 15706 Santiago de Compostela, Spain.
  • Abal M; Translational Medical Oncology, Health Research Institute of Santiago (IDIS), University Hospital of Santiago (SERGAS), Trav. Choupana s/n 15706 Santiago de Compostela, Spain.
Sci Rep ; 6: 37820, 2016 11 30.
Article en En | MEDLINE | ID: mdl-27901069
Knowledge on the molecular mechanisms underlying metastasis colonization in Non-Small Cell Lung Cancer (NSCLC) remains incomplete. A complete overview integrating driver mutations, primary tumour heterogeneity and overt metastasis lacks the dynamic contribution of disseminating metastatic cells due to the inaccessibility to the molecular profiling of Circulating Tumour Cells (CTCs). By combining immunoisolation and whole genome amplification, we performed a global gene expression analysis of EpCAM positive CTCs from advanced NSCLC patients. We identified an EpCAM+ CTC-specific expression profile in NSCLC patients mostly associated with cellular movement, cell adhesion and cell-to-cell signalling mediated by PI3K/AKT, ERK1/2 and NF-kB pathways. NOTCH1 emerged as a driver connecting active signalling pathways, with a reduced number of related candidate genes (NOTCH1, PTP4A3, LGALS3 and ITGB3) being further validated by RT-qPCR on an independent cohort of NSCLC patients. In addition, these markers demonstrated high prognostic value for Progression-Free Survival (PFS). In conclusion, molecular characterization of EpCAM+ CTCs from advanced NSCLC patients provided with highly specific biomarkers with potential applicability as a "liquid biopsy" for monitoring of NSCLC patients and confirmed NOTCH1 as a potential therapeutic target to block lung cancer dissemination.
Asunto(s)

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Carcinoma de Pulmón de Células no Pequeñas / Receptor Notch1 / Neoplasias Pulmonares / Células Neoplásicas Circulantes Tipo de estudio: Prognostic_studies Idioma: En Revista: Sci Rep Año: 2016 Tipo del documento: Article

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Carcinoma de Pulmón de Células no Pequeñas / Receptor Notch1 / Neoplasias Pulmonares / Células Neoplásicas Circulantes Tipo de estudio: Prognostic_studies Idioma: En Revista: Sci Rep Año: 2016 Tipo del documento: Article